- Home>
- Journal Watch
- >
- breast tumors
Search for breast tumors in all Journal Watch editions
Physician-authored summaries on the latest research on breast tumors, editorials on breast tumors, and perspectives on breast tumors - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 562 results - Relevance
- Date
You searched for: breast tumors
-
Circulating Tumor DNA Tracks Metastatic Breast Cancer in Proof-of-Concept Study Free
- March 14, 2013
- Physician's First Watch
A small study — deemed "more encouraging than definitive" by commentators — shows that circulating DNA from breast tumors can be used to track progression in metastatic... -
Screening Mammography: Does Overdiagnosis Overshadow Prevention of Advanced Breast Cancer? Free
- November 21, 2012
- Andrew M. Kaunitz, MD
- Women's Health
Analysis of U.S. data spanning 30 years suggests many mammographically detected tumors are destined to be harmless.- Reviewing:
- Bleyer A and Welch HG., N Engl J Med 2012 Nov 22; 367:1998.
-
The Manhattan Project of Breast Cancer
- October 9, 2012
- William J. Gradishar, MD
- Oncology and Hematology
Comprehensive molecular studies of breast tumors from the Cancer Genome Atlas Network could lead to more effective personalized therapies.- Reviewing:
- The Cancer Genome Atlas Network., Nature 2012 Sep 23;:
-
Goserelin Does Not Preserve Ovarian Function During Chemotherapy
- July 26, 2011
- William J. Gradishar, MD
- Oncology and Hematology
This luteinizing-hormone–releasing hormone agonist was of no benefit for young women receiving anthracycline-based adjuvant chemotherapy for breast cancer.- Reviewing:
- Gerber B et al., J Clin Oncol 2011 Jun 10; 29:2334.
-
ASCO 2010 Report: Breast Cancer Free
- July 13, 2010
- William J. Gradishar, MD
- Oncology and Hematology
Key trials focused on surgical approaches, eribulin, and bevacizumab plus chemotherapy. -
Postmastectomy Radiation Therapy for Early-Stage Breast Cancer
- June 22, 2010
- William J. Gradishar, MD
- Oncology and Hematology
Given low locoregional recurrence rates among many patients who do not undergo this treatment, recommendations for its use should be reconsidered.- Reviewing:
- Sharma R et al., Ann Surg Oncol 2010 May 5;:
-
In Breast Cancer, Not All Small Tumors Are Equal
- January 5, 2010
- William J. Gradishar, MD
- Oncology and Hematology
Tumors =1 cm that are positive for HER2 more commonly recur than HER2-negative tumors.- Reviewing:
- Curigliano G et al., J Clin Oncol 2009 Dec 1; 27:5693. Gonzalez-Angulo AM et al., J Clin Oncol 2009 Dec 1; 27:5700.
-
Can Anthracycline Response Be Predicted from HER2 and TOP2A Status of Breast Tumors?
- October 6, 2009
- William J. Gradishar, MD
- Oncology and Hematology
The predictive value of these genetic markers remains unclear.- Reviewing:
- Tubbs R et al., J Clin Oncol 2009 Aug 20; 27:3881. Pritchard KI., J Clin Oncol 2009 Aug 20; 27:3875.
-
Screening Detects Many Breast Cancers, but How Many Are Overdiagnosed?
- August 6, 2009
- Wendy S. Biggs, MD
- Women's Health
Population-wide mammography screening is associated with higher incidence of breast cancer, but the estimated overdiagnosis rate is more than 50%.- Reviewing:
- Jørgensen KJ and Gøtzsche PC., BMJ 2009 Jul 9; 339:b2587. Welch HG., BMJ 2009 Jul 9; 339:b1425.
-
Are Anthracyclines Justified for Breast Cancer?
- June 2, 2009
- William J. Gradishar, MD
- Oncology and Hematology
Most patients are not likely to benefit from anthracycline-based adjuvant chemotherapy.- Reviewing:
- O’Malley FP et al., J Natl Cancer Inst 2009 May 6; 101:644. Slamon DJ and Press MF., J Natl Cancer Inst 2009 May 6; 101:615.
-
Factors Associated with Triple-Negative Breast Cancer Remain Elusive in Black Women
- April 30, 2009
- Andrew M. Kaunitz, MD
- Women's Health
Likelihood of poor-prognosis tumors in black women was not explained by BMI.- Reviewing:
- Stead LA et al., Breast Cancer Res 2009 Mar 25; 11:R18.
-
The Effect of Food on Lapatinib Bioavailability
- April 7, 2009
- William J. Gradishar, MD
- Oncology and Hematology
When administered with food, lapatinib bioavailability was substantially higher than when given to fasted patients.- Reviewing:
- Koch KM et al., J Clin Oncol 2009 Mar 10; 27:1191.
-
Second Breast Cancers: Early Detection Remains Important
- April 2, 2009
- Andrew M. Kaunitz, MD
- Women's Health
Retrospective analysis underscores the value of close clinical and mammographic follow-up of breast cancer survivors.- Reviewing:
- Houssami N et al., Ann Oncol 2009 Mar 17;:
-
Even Small HER2-Positive Tumors May Require Aggressive Treatment Free
- December 15, 2008
- Physician's First Watch
Patients may ask about a widely reported study suggesting that even some very small breast tumors may require aggressive treatment after surgery. The findings were... -
Mechanism of ER-Negative Breast Cancer in BRCA1-Mutation Carriers Free
- December 11, 2007
- William J. Gradishar, MD
- Oncology and Hematology
BRCA1 protein directly regulates the estrogen-receptor α gene by binding to its promoter.- Reviewing:
- Hosey AM et al., J Natl Cancer Inst 2007 Nov 13;: Jordan VC., J Natl Cancer Inst 2007 Nov 13;:
-
Gene Signatures Predict Response to Cancer Therapy
- December 4, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Identifying patients who will not respond to standard chemotherapy would permit direct entry into investigational regimens.- Reviewing:
- Bonnefoi H et al., Lancet Oncol 2007 Nov 14;:
-
CHF in Older Women After Adjuvant Anthracycline-Based Chemotherapy for Breast Cancer Free
- October 30, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Adjuvant therapy that includes anthracyclines raises risk for adverse cardiac events.- Reviewing:
- Pinder MC et al., J Clin Oncol 2007 Sep 1; 25:3808.
-
Breast Tumors in Black Women More Likely to Be Estrogen-Receptor Negative Free
- September 7, 2007
- Physician's First Watch
Breast cancer is more likely to be estrogen-receptor negative in black women than in white women, according to findings that will be presented this... -
Preoperative Trastuzumab, Docetaxel, and Carboplatin for HER2-Positive Breast Cancer
- June 18, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Preoperative trastuzumab benefits some patients with HER2-positive tumors and increases the number of patients who can undergo breast-conserving surgery.- Reviewing:
- Coudert BP et al., J Clin Oncol 2007 May 21;: Buzdar AU et al., Clin Cancer Res 2007 Jan 1; 13:228-33.
-
Plasma Prolactin Levels Influence Breast Cancer Development
- April 13, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Prolactin probably plays a role in the etiology of breast cancer, particularly ER+ breast cancer, among both premenopausal and postmenopausal women.- Reviewing:
- Tworoger SS et al., J Clin Oncol 2007 Mar 19;:
Sort by:
Items 1 to 20 of 562 results - Relevance
- Date
